Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

heamatology

- PMLiVE

Celgene bid to push Revlimid beyond myeloma blocked again

Cancer treatment fails phase III trial in lymphoma

Strategic symbionts

Strategic alliances are becoming more interesting and more important 

Sanofi reception

Sanofi wins EU approval for new diabetes combination Suliqua

European Commission licenses the once-daily version of Lantus and Lyxumia

UK flag

May says UK’s science base is a “negotiating priority” for Brexit

Stokes confidence in UK pharma as science and innovation featured among 12 key priorities

- PMLiVE

Brexit – a tough pill to swallow

What will be expected of the UK when the post-Brexit environment takes shape?

- PMLiVE

Gilead’s Hepatitis B therapy Vemlidy granted EU approval

Treatment shows similar efficacy to the firm's Viread at one-tenth of dosage

- PMLiVE

The future of biotech

What impact will the sector, and its R&D performance, have on pharma?

- PMLiVE

Neurodegenerative disorders market set to reach $45bn by 2022

But shake-up expected from flurry of new approvals and patent expirations

Celgene to apply machine learning to market access

Signs agreement for rights to GNS Healthcare's simulation platform

- PMLiVE

Hanover Health opens market access practice

New practice will be led by director Jing Wang-Silvanto

- PMLiVE

FDA green light for Pfizer’s eczema drug

Blockbuster-hopeful Eucrisa expected to launch early next year at $580 per 60mg tube

- PMLiVE

Global drug spending will rise by a third to $1.5trn in 2021

However, rate of growth will not match previous years due to pricing and access pressures

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links